| NCT ID | NCT07885436 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Xiamen University |
| Condition | Solid Tumor (Excluding CNS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-10-22 |
| Primary Completion | 2027-10-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-10-22 with a primary completion date of 2027-10-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to evaluate the feasibility of 68Ga-XHER2 PET/CT as a noninvasive imaging approach for assessing HER2 expression in patients with solid tumors and to investigate the correlation between tracer uptake and pathological HER2 expression.
Eligibility Criteria
Inclusion Criteria: * adult patients (aged 18 years or older) * patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report) * patients who had scheduled both standard-of-care imaging and 68Ga-XHER2 PET/CT scans * patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee Exclusion Criteria: * patients with pregnancy * the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07885436 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Solid Tumor (Excluding CNS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07885436 currently recruiting?
Yes, NCT07885436 is actively recruiting participants. Contact the research team at wzhaoliang01@163.com for enrollment information.
Where is the NCT07885436 trial being conducted?
This trial is being conducted at Xiamen, China.
Who is sponsoring the NCT07885436 clinical trial?
NCT07885436 is sponsored by The First Affiliated Hospital of Xiamen University. The trial plans to enroll 80 participants.